StockNews.com Begins Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)

StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Bellicum Pharmaceuticals Stock Down 6.6 %

Shares of BLCM opened at $0.07 on Tuesday. The firm’s 50 day moving average price is $0.08 and its 200 day moving average price is $0.14. Bellicum Pharmaceuticals has a twelve month low of $0.06 and a twelve month high of $1.31.

Hedge Funds Weigh In On Bellicum Pharmaceuticals

An institutional investor recently bought a new position in Bellicum Pharmaceuticals stock. HRT Financial LP bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned approximately 0.42% of Bellicum Pharmaceuticals as of its most recent filing with the SEC. 4.93% of the stock is owned by hedge funds and other institutional investors.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.